Osage University Partners has helped the UT Southwestern precision medicine spinout close a round which will be used to advance and expand its pipeline of respiratory disease drug candidates.

Recode Therapeutics, a US-based biopharmaceutical spinout of University of Texas Southwestern Medical Center, completed an $80m series B round backed by Osage University Partners (OUP) on Wednesday. Pharmaceutical company Pfizer on Wednesday and investment adviser EcoR1 Capital co-led the round, and also included pharmaceutical firm Sanofi, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.